Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.nejm.org/doi/full/10.1056" to "https://doi.org/10.1056") |
m |
||
| Line 5: | Line 5: | ||
{{#lst:Section editor transclusions|heme}} | {{#lst:Section editor transclusions|heme}} | ||
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | '''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | ||
| − | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 12: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=All lines of therapy= | =All lines of therapy= | ||
| − | |||
==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:be34d7|Variant=1}}=== | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
| Line 22: | Line 19: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] |
|style="background-color:#ffffbe"|Pilot, <20 pts | |style="background-color:#ffffbe"|Pilot, <20 pts | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
*[[Plerixafor (Mozobil)]] | *[[Plerixafor (Mozobil)]] | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
| − | # McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30625055 PubMed] | + | # McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30625055 PubMed] |
| − | |||
[[Category:WHIM syndrome regimens]] | [[Category:WHIM syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Cytopenias]] | [[Category:Cytopenias]] | ||
Revision as of 15:06, 26 February 2023
Section editor transclusions WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
References
- McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article PubMed